Non-small cell lung cancer beyond biomarkers: The evolving landscape of clinical trial design

15Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

The approval of EGFR and ALK directed tyrosine kinase inhibitors materialized the concept of tailoring therapy on the basis of specific biomarkers for treating patients with NSCLC. Research for other biologics, although demonstrating clinical benefit, has been less successful so far for producing biomarkers that predict response. Blocking angiogenesis is the prototype for the agents that belong in the latter group that target specific molecules, yet they are currently approved for relatively unselected groups of patients. In order to meet the goal of personalizing care in the various settings of NSCLC, a wealth of biologics and compounds are currently being tested in clinical trials in different phases of clinical development. In a subset of the relevant studies, a biomarker perspective is appreciated. This review summarizes the clinical rationale of the major ongoing phase II and III NSCLC studies that employ targeting specific molecules with novel agents, as well as innovative strategies, and includes a comparative discussion of the different designs. © 2014 by the authors; licensee MDPI, Basel, Switzerland.

Cite

CITATION STYLE

APA

Dimou, A., & Papadimitrakopoulou, V. (2014). Non-small cell lung cancer beyond biomarkers: The evolving landscape of clinical trial design. Journal of Personalized Medicine. MDPI AG. https://doi.org/10.3390/jpm4030386

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free